Evidence map›Paper›PMID 38653873›Full record

ArticleWiener klinische Wochenschrift2024

External quality assessments for SARS-CoV-2 genome detection in Austria : A comparison of the first postpandemic round with results from the pandemic era.

Christoph Buchta, Stephan W Aberle, Irene Görzer, Andrea Griesmacher, Mathias M Müller, Erich Neuwirth, Elisabeth Puchhammer-Stöckl, Lukas Weseslindtner, Jeremy V Camp

Abstract readComparative Study
In one paragraph

Article in Wiener klinische Wochenschrift, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christoph BuchtaAustrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Hörlgasse 18/5, 1090, Vienna, Austria.
Stephan W AberleCenter for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.
Irene GörzerCenter for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.
Andrea GriesmacherAustrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Hörlgasse 18/5, 1090, Vienna, Austria.
Mathias M MüllerAustrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Hörlgasse 18/5, 1090, Vienna, Austria.
Erich NeuwirthFaculty of Computer Science, University of Vienna, Vienna, Austria.
Elisabeth Puchhammer-StöcklCenter for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.
Lukas WeseslindtnerCenter for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.
Jeremy V CampCenter for Virology, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria. jeremy.camp@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-9040-5786

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExternal quality assessment (EQA) schemes provide objective feedback to participating laboratories about the performance of their analytical systems and information about overall regional analytical performance. The EQAs are particularly important during pandemics as they also assess the reliability of individual test results and show opportunities to improve test strategies. With the end of the COVID-19 pandemic, the testing frequency significantly decreased in Austria. Here, we analyzed whether this decrease had an effect on participation and/or performance in SARS-CoV‑2 virus detection EQAs, as compared to the pandemic era. MATERIAL AND

methodsIdentical samples were sent to all participating laboratories, and the EQA provider evaluated the agreement of the reported results with defined targets. The EQA was operated under two schemes with identical samples and therefore we analyzed it as a single EQA round. The performance of testing was reported as true positive ratios, comparing the post-pandemic data to previous rounds. Furthermore, subgroups of participants were analyzed stratified by laboratory type (medical or nonmedical) and the test system format (fully automated or requiring manual steps).

resultsWhile the frequency of false negative results per sample did not change during the 3 years of the pandemic (5.7%, 95% confidence interval [CI] 3.1-8.4%), an average per sample false negative ratio of 4.3% was observed in the first post-pandemic EQA (0%, 1.8%, and 11% for the 3 positive samples included in the test panel, n = 109 test results per sample). In this first post-pandemic EQA medical laboratories (average 0.4% false negative across 3 samples, n = 90) and automated test systems (average 1.2% false negative, n = 261) had lower false negative ratios than nonmedical laboratories (22.8%, n = 19) and manual test systems (16.7%, n = 22). These lower average ratios were due to a low concentration sample, where nonmedical laboratories reported 36.8% and manual test systems 54.5% true positive results.

conclusionOverall ratios of true positive results were below the mean of all results during the pandemic but were similar to the first round of the pandemic. A lower post-pandemic true positive ratio was associated with specific laboratory types and assay formats, particularly for samples with low concentration. The EQAs will continue to monitor the laboratory performance to ensure the same quality of epidemiological data after the pandemic, even if vigilance has decreased.

Indexed as

COVID-19PandemicsQuality Assurance, Health CareSARS-CoV-2AustriaCOVID-19 Nucleic Acid TestingHumansLaboratories, ClinicalReproducibility of ResultsCOVID-19DiagnosticsMolecularNATPCRVirus genome detection

Identifiers

PMID38653873
PMCPMC11327175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.